#USA #medical technology #Cardiff-by-the-Sea #Field Medical #Mark A. Turco

Field Medical's New Leadership

Field Medical, Inc., a pioneering firm specializing in medical technology, has announced the appointment of Dr. Mark A. Turco, MD, as its new Chief Executive Officer. This change, effective immediately, comes at a crucial time as the company focuses on advancing its clinical-stage solutions in the realm of second-generation pulsed field ablation (PFA) for complex cardiac arrhythmias.

A Wealth of Experience

Dr. Turco brings to Field Medical an impressive portfolio of over 30 years in leadership roles, particularly in the cardiovascular space. His background includes both executive positions in large medical device companies and leadership in venture-capital-backed startups. Having effectively led several clinically-focused organizations through critical development and strategic operational phases, Dr. Turco is uniquely positioned to guide Field Medical during its next growth trajectory.

Ben Cannon, a member of Field Medical’s board of directors and part of the investment teams at BioStar Capital and Cue Growth, expressed confidence in Dr. Turco’s capabilities, stating, "Mark's unique background as a cardiologist, clinical researcher, and executive with extensive experience in medical devices equips him to lead Field Medical in this next phase of growth."

Proven Track Record

Before joining Field Medical, Dr. Turco served as President and CEO of JC Medical, Inc. During his tenure, he spearheaded the development of an innovative transcatheter aortic valve replacement (TAVR) system for treating aortic insufficiency, which was acquired by Edwards Lifesciences in 2024. His earlier roles also include significant positions at Medtronic and Covidien, where he served as Vice President and Chief Medical Officer focusing on vascular and neurovascular divisions. Recently, he was the President and CEO of the Rhode Island Life Science Hub, enhancing his operational insights further.

Upon his appointment, Dr. Turco stated, "It is an honor to join Field Medical at such a crucial time in its evolution. The firm has established a distinctive PFA platform that can significantly address the unmet needs of patients with both ventricular arrhythmias and atrial fibrillation. I look forward to closely collaborating with the exceptional team at Field Medical to rigorously advance our clinical programs and navigate the regulatory pathways to achieve our operational goals."

The Future of Field Medical

Founded in 2022, Field Medical is dedicated to creating state-of-the-art solutions for complex cardiac arrhythmias. Their flagship system, FieldForce, merges a specialized catheter design with patented FieldBending™ energy technology aimed at achieving safe and effective ablations. The company recently received recognition as an innovative device and participated in the FDA TAP Pilot Program for its ventricular tachycardia indication.

With the clinical trial VCAS published in Circulation in October 2025, Field Medical is poised to make significant strides in medical technology. As the company embarks on this new chapter under Dr. Turco's leadership, there is keen anticipation of the impact their innovations will have on patient care in cardiology.

For updates and more details about their initiatives, visit Field Medical's official website and follow them on LinkedIn, X, and YouTube.

Note: The FieldForce™ ablation system is currently an investigational device, and according to federal law, its use is limited to research purposes.